Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En fase III-studie av HMPL-760 i kombinasjon med R-GemOx versus placebo i kombinasjon med R-GemOx ved relapserende/refraktær DLBCL

9. november 2026 oppdatert av: Hutchmed

En fase III randomisert, dobbelblind, positivkontrollert studie for å evaluere effekt, sikkerhet og farmakokinetikk av HMPL-760 i kombinasjon med R-GemOx versus placebo i kombinasjon med R-GemOx hos pasienter med tilbakefallende/refraktær diffus storcelle lymfom (DLBCL)

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Studieoversikt

Detaljert beskrivelse

The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

The target population of this study includes patients with DLBCL who are relapsed or refractory.

Studietype

Intervensjonell

Registrering (Antatt)

240

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Baoding, Kina
        • Rekruttering
        • Baoding NO.1 Central Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Haiying Yao
      • Beijing, Kina
        • Rekruttering
        • Beijing GoBroad Hospital
        • Hovedetterforsker:
          • Kai Hu
        • Ta kontakt med:
      • Beijing, Kina
        • Rekruttering
        • BEIJING TONGREN HOSPITAL, Capital Medical University
        • Hovedetterforsker:
          • Liang Wang
        • Ta kontakt med:
      • Bengbu, Kina
        • Rekruttering
        • The First Affiliated Hospital of Bengbu Medical College
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yanli Yang
      • Changchun, Kina
        • Rekruttering
        • The First Hospital of Jilin University
        • Hovedetterforsker:
          • Ou Bai
        • Ta kontakt med:
      • Changsha, Kina
        • Rekruttering
        • Hunan Cancer Hospital
        • Hovedetterforsker:
          • Hui Zhou
        • Ta kontakt med:
      • Changsha, Kina
        • Rekruttering
        • The Second Xiangya Hospital of Central South University
        • Hovedetterforsker:
          • Hongling Peng
        • Ta kontakt med:
      • Changsha, Kina
        • Rekruttering
        • People's Hospital of Hunan Province
        • Ta kontakt med:
        • Hovedetterforsker:
          • Can Liu
      • Chengdu, Kina
        • Rekruttering
        • West China Hospital of Sichuan University
        • Hovedetterforsker:
          • Liqun Zou
        • Ta kontakt med:
      • Chengdu, Kina
        • Rekruttering
        • Sichuan Provincial People's Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xiaobing Huang
      • Chongqing, Kina
        • Rekruttering
        • The First Affiliated Hospital of Chongqing Medical University
        • Hovedetterforsker:
          • Xin Wang
        • Ta kontakt med:
      • Chongqing, Kina
        • Rekruttering
        • Chongqing University Cancer Hospital
        • Hovedetterforsker:
          • Yao Liu
        • Ta kontakt med:
      • Fujian, Kina
        • Rekruttering
        • Quanzhou First Hospital.Fujian
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xiongpeng Zhu
      • Fuzhou, Kina
        • Rekruttering
        • Fujian Medical University Union Hospital
        • Hovedetterforsker:
          • Jianzhen Shen
        • Ta kontakt med:
      • Guangzhou, Kina
        • Rekruttering
        • Sun Yat-sen University Cancer Center
        • Hovedetterforsker:
          • Zhiming Li
        • Ta kontakt med:
      • Guangzhou, Kina
        • Rekruttering
        • Guangdong Provincial People's Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xiaojuan Wei
      • Guangzhou, Kina
        • Rekruttering
        • ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
        • Hovedetterforsker:
          • Yuhua Li
        • Ta kontakt med:
      • Guiyang, Kina
        • Rekruttering
        • The Affiliated Hospital of Guizhou Medical University
        • Hovedetterforsker:
          • Yan Zhang
        • Ta kontakt med:
      • Hangzhou, Kina
        • Rekruttering
        • Zhejiang Cancer Hospital
        • Hovedetterforsker:
          • Haiyan Yang
        • Ta kontakt med:
      • Hangzhou, Kina
        • Rekruttering
        • The First Affiliated Hospital, Zhejiang University
        • Hovedetterforsker:
          • Zhen Cai
        • Ta kontakt med:
      • Harbin, Kina
        • Rekruttering
        • Harbin Medical University Cancer Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Qingyuan Zhang
      • Hefei, Kina
        • Rekruttering
        • The Second Affiliated Hospital of Anhui Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Zhimin Zhai
      • Jinan, Kina
        • Rekruttering
        • Qilu Hospital of Shandong University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Shuqian Xu
      • Jinan, Kina
        • Rekruttering
        • Shandong Cancer Hospital & Institute
        • Hovedetterforsker:
          • Zengjun Li
        • Ta kontakt med:
      • Kunming, Kina
        • Har ikke rekruttert ennå
        • The First Affiliated Hospital of Kunming Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mingxia Shi
      • Nanchang, Kina
        • Rekruttering
        • Jiangxi Cancer Hospital
        • Hovedetterforsker:
          • Yan Huang
        • Ta kontakt med:
      • Nanjing, Kina
        • Rekruttering
        • Jiangsu Cancer Hospital
        • Hovedetterforsker:
          • Yan Zhang
        • Ta kontakt med:
      • Nanjing, Kina
        • Rekruttering
        • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jingyan Xu
      • Nanning, Kina
        • Rekruttering
        • The First Affiliated Hospital of Guangxi Medical University
        • Hovedetterforsker:
          • Zhigang Peng
        • Ta kontakt med:
      • Qingdao, Kina
        • Rekruttering
        • The Affiliated Hospital of Qingdao University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xia Zhao
      • Shanghai, Kina
        • Rekruttering
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Hovedetterforsker:
          • Weili Zhao
        • Ta kontakt med:
      • Shanghai, Kina
        • Rekruttering
        • Tongji Hospital of Tongji University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ping Li
      • Shanghai, Kina
        • Har ikke rekruttert ennå
        • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
        • Hovedetterforsker:
          • Ligen Liu
        • Ta kontakt med:
      • Shenyang, Kina
        • Rekruttering
        • Shengjing Hospital of China Medical University
        • Hovedetterforsker:
          • Wei Yang
        • Ta kontakt med:
      • Shenzhen, Kina
        • Rekruttering
        • Shenzhen people's hospital
        • Hovedetterforsker:
          • Jihao Zhou
        • Ta kontakt med:
      • Taiyuan, Kina
        • Rekruttering
        • Shanxi Provincial Cancer Hospital
        • Hovedetterforsker:
          • Liping Su
        • Ta kontakt med:
      • Tangshan, Kina
        • Rekruttering
        • North China University of Science and Technology Affiliated Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Zhenyu Yan
      • Tianjin, Kina
        • Rekruttering
        • Tianjin Medical University Cancer Institute & Hospital
        • Hovedetterforsker:
          • Zhengzi Qian
        • Ta kontakt med:
          • Zhengzi Qian
          • Telefonnummer: 13702031222
          • E-post: qzz@163.com
      • Tianjin, Kina
        • Rekruttering
        • Tianjin People's Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xingli Zhao
      • Tianjin, Kina
        • Rekruttering
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
        • Hovedetterforsker:
          • Dehui Zou
        • Ta kontakt med:
      • Wenzhou, Kina
        • Rekruttering
        • The First Affiliated Hospital of WMU
        • Ta kontakt med:
        • Hovedetterforsker:
          • Songfu Jiang
      • Wuhan, Kina
        • Rekruttering
        • Hubei Cancer Hospital
        • Hovedetterforsker:
          • Huijing Wu
        • Ta kontakt med:
      • Wuhan, Kina
        • Rekruttering
        • Wuhan Union Hospital of China
        • Hovedetterforsker:
          • Liling Zhang
        • Ta kontakt med:
      • Xi'an, Kina
        • Rekruttering
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Hovedetterforsker:
          • Pengcheng He
        • Ta kontakt med:
      • Xi'an, Kina
        • Rekruttering
        • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
        • Hovedetterforsker:
          • Jie Liu
        • Ta kontakt med:
      • Xiamen, Kina
        • Har ikke rekruttert ennå
        • The First Affiliated Hospital of Xiamen University
        • Hovedetterforsker:
          • Bing Xu
        • Ta kontakt med:
      • Xuzhou, Kina
        • Rekruttering
        • The Affiliated Hospital of Xuzhou Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Wei Sang
      • Zhengzhou, Kina
        • Rekruttering
        • Henan Cancer Hospital
        • Hovedetterforsker:
          • Keshu Zhou
        • Ta kontakt med:
      • Zhengzhou, Kina
        • Rekruttering
        • The First Affiliated Hospital of Zhengzhou University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xudong Zhang
      • Ürümqi, Kina
        • Rekruttering
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Hovedetterforsker:
          • Yan Li
        • Ta kontakt med:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina
        • Rekruttering
        • Fudan University Shanghai Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Fangfang Lv

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Sign the ICF and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. ECOG performance status score between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally measurable lesion;
  7. Expected survival is more than 12 weeks;

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  8. Clinically significant active infection;

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: The experimental group

Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Patients will receive HMPL-760 once daily (QD) orally.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Andre navn:
  • Gemcitabinhydroklorid til injeksjon
  • Rituximab injeksjon
  • Oxaliplatin-injeksjon
Placebo komparator: The control group

Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Andre navn:
  • Gemcitabinhydroklorid til injeksjon
  • Rituximab injeksjon
  • Oxaliplatin-injeksjon

Patients will receive HMPL-760 placebo once daily (QD) orally.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-free survival (PFS)
Tidsramme: Up to approximately two years

Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.

Up to approximately two years
End of treatment (EOT)
Tidsramme: Up to approximately two years

Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).

Up to approximately two years
Systemic antitumor therapy
Tidsramme: Up to approximately two years

Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).

Up to approximately two years
Overall survival (OS)
Tidsramme: Up to approximately two years

OS is defined as the time from randomization to death due to any cause.

Up to approximately two years
systematic anti-tumor therapy
Tidsramme: Up to approximately two years

OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).

Up to approximately two years
Premature withdrawal from study treatment
Tidsramme: Up to approximately two years

OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).

Up to approximately two years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Independent review committee (IRC)-assessed PFS
Tidsramme: Up to approximately two years

Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

Up to approximately two years
IRC- and investigator-assessed objective response rate (ORR)
Tidsramme: Up to approximately two years

Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR)

Up to approximately two years
IRC- and investigator-assessed complete response rate (CRR)
Tidsramme: Up to approximately two years

Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR)

Up to approximately two years
IRC- and investigator-assessed duration of response (DoR)
Tidsramme: Up to approximately two years

For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first

Up to approximately two years
IRC- and investigator-assessed clinical benefit rate (CBR)
Tidsramme: Up to approximately two years

Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)

Up to approximately two years
IRC- and investigator-assessed time to response (TTR)
Tidsramme: Up to approximately two years

Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR)

Up to approximately two years
Safety Endpoints
Tidsramme: Up to approximately two years
  • Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious adverse events (TESAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 (NCI CTCAE 6.0).
  • Changes in laboratory tests, vital signs, 12-lead ECG, etc.
Up to approximately two years
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Tidsramme: At the end of Cycle 4 (each cycle is 21 days)]

including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

At the end of Cycle 4 (each cycle is 21 days)]

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Biomarker assessment
Tidsramme: Up to approximately two years

Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy.

Up to approximately two years
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Tidsramme: Up to approximately two years

Human metabolites of HMPL-760 when co-administered with R-GemOx

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years

maximum concentration in steady-state (Cmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years

time to maximum concentration in steady-state (Tmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years

Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years

The rate at which the drug is eliminated from the body (CL/F) (if applicable )

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years

The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable)

Up to approximately two years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Weili Zhao, Ruijin Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. mars 2026

Primær fullføring (Antatt)

30. april 2028

Studiet fullført (Antatt)

30. desember 2028

Datoer for studieregistrering

Først innsendt

28. januar 2026

Først innsendt som oppfylte QC-kriteriene

6. februar 2026

Først lagt ut (Faktiske)

13. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere